$0.03 EPS Expected for BioLife Solutions Inc (BLFS) This Quarter

Equities analysts expect BioLife Solutions Inc (NASDAQ:BLFS) to report earnings of $0.03 per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for BioLife Solutions’ earnings, with estimates ranging from $0.02 to $0.04. BioLife Solutions posted earnings of ($0.01) per share during the same quarter last year, which would indicate a positive year over year growth rate of 400%. The business is scheduled to report its next earnings report on Thursday, May 9th.

According to Zacks, analysts expect that BioLife Solutions will report full year earnings of $0.13 per share for the current year, with EPS estimates ranging from $0.11 to $0.15. For the next year, analysts anticipate that the firm will post earnings of $0.30 per share, with EPS estimates ranging from $0.29 to $0.30. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, March 14th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.04. BioLife Solutions had a net margin of 16.54% and a return on equity of 11.15%. The business had revenue of $5.46 million for the quarter, compared to analyst estimates of $5.47 million.

A number of equities analysts recently weighed in on BLFS shares. BidaskClub upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. ValuEngine upgraded shares of BioLife Solutions from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 28th. Zacks Investment Research lowered shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Finally, Janney Montgomery Scott upgraded shares of BioLife Solutions to a “buy” rating and set a $5.00 price target on the stock in a research report on Thursday, December 20th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. BioLife Solutions currently has an average rating of “Buy” and a consensus price target of $17.75.

BLFS opened at $19.53 on Friday. The stock has a market cap of $364.27 million, a P/E ratio of 139.50 and a beta of 1.65. BioLife Solutions has a twelve month low of $4.85 and a twelve month high of $26.35.

In other BioLife Solutions news, CFO Greef Roderick De sold 10,000 shares of BioLife Solutions stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $19.83, for a total transaction of $198,300.00. Following the transaction, the chief financial officer now directly owns 40,359 shares of the company’s stock, valued at $800,318.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Todd Berard sold 3,000 shares of BioLife Solutions stock in a transaction dated Tuesday, January 15th. The stock was sold at an average price of $12.12, for a total transaction of $36,360.00. Following the transaction, the vice president now directly owns 37,583 shares in the company, valued at $455,505.96. The disclosure for this sale can be found here. Insiders have sold 67,957 shares of company stock worth $1,044,985 over the last ninety days. 38.50% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the business. Canton Hathaway LLC purchased a new position in BioLife Solutions during the fourth quarter worth about $66,000. GSA Capital Partners LLP purchased a new stake in shares of BioLife Solutions in the 3rd quarter valued at approximately $200,000. Northern Trust Corp raised its stake in shares of BioLife Solutions by 24.4% in the 2nd quarter. Northern Trust Corp now owns 16,304 shares of the medical equipment provider’s stock valued at $186,000 after acquiring an additional 3,200 shares during the period. Monashee Investment Management LLC purchased a new stake in shares of BioLife Solutions in the 3rd quarter valued at approximately $337,000. Finally, Weiss Multi Strategy Advisers LLC purchased a new stake in shares of BioLife Solutions in the 4th quarter valued at approximately $241,000. 40.67% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Further Reading: What does the Producer Price Index (PPI) tell investors?

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.